(Q39334333)

English

Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

15

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

John R. Mascola

13

object named as

John Mascola

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

David C. Montefiori

12

object named as

David Montefiori

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

author name string

Ranajit Pal

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

V S Kalyanaraman

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

B C Nair

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Stephen Whitney

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Timothy Keen

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Lindsey Hocker

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Lauren Hudacik

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Nicolas Rose

8

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Innocent Mboudjeka

9

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Siyuan Shen

10

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Te-Hui Wu-Chou

11

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Philip Markham

14

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

0 references

publication date

1 May 2006

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

348

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

341-353

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone

2 references

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

based on heuristic

inferred from DOI database lookup

Cutaneous antigen priming via gene gun leads to skin-selective Th2 immune-inflammatory responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

DNA vaccines against human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Progress in the development of an HIV-1 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Progress toward an HIV vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Prospects for vaccine protection against HIV-1 infection and AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Vaccines for the prevention of HIV-1 disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Virological rebound after suppression on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Challenges and opportunities for development of an AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

HIV-1 diversity and vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Characterization of a simian human immunodeficiency virus encoding the envelope gene from the CCR5-tropic HIV-1 Ba-L.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Immunopathogenesis of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Reduced immunogenicity of DNA vaccine plasmids in mixtures

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

The moving target: mechanisms of HIV persistence during primary infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Characterization of primary isolate-like variants of simian-human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

based on heuristic

inferred from DOI database lookup

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2005.12.029

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39334333&oldid=1820601708"